Neuropsychological drivers of epilepsy medication adherence

Staying on track with antiseizure medication is one of the most persistent challenges in chronic neurological care. Forgetfulness, complex regimens, side effects, and shifting motivation all conspire against the simple act of swallowing a pill on schedule. Over the past decade, neuropsychologists have moved beyond describing this problem to actively mapping the cognitive and emotional fingerprints that predict who is most likely to struggle.

In Australian outpatient clinics, where neurologists see hundreds of patients each month, screening for these predictors is becoming routine. The conversation has shifted from "Are you taking your tablets?" to "What gets in the way of taking them, and what helps?" That change of framing owes much to work presented at gatherings including the INS mid-year meeting in Prague and to ongoing Australian-led research.

Why adherence remains a clinical puzzle

Across Australia, hospital pharmacies dispense thousands of repeat prescriptions every month, yet adherence rates for chronic conditions rarely exceed seventy per cent. For people with epilepsy, even occasional missed doses raise the risk of breakthrough seizures, emergency department visits, and lost driving privileges, a particularly heavy cost in outer suburbs of cities like Perth or Adelaide, where driving is essential to daily life.

The factors that drive non-adherence are layered. Pharmacological complexity, cost, beliefs about medication, and cognitive load each play a role. Neuropsychological research has sharpened the lens on the cognitive side, identifying specific domains where measurable weakness lines up with missed doses.

Memory profiles and missed doses

Verbal memory, in particular, has emerged as a strong candidate. Patients who struggle to recall a short story or a list of words ten minutes after hearing it tend to be the same ones who forget whether they took their morning dose. Working memory, the mental scratchpad that holds information while you act on it, is implicated in switching pills correctly between morning and evening routines.

Clinicians at the Royal Melbourne Hospital and the Prince of Wales in Sydney have started pairing brief memory assessments alongside prescription refills. The link is strong enough that some researchers argue episodic and working memory tasks should be embedded into standard epilepsy reviews.

Executive dysfunction and daily planning

Planning, initiation, and cognitive flexibility, the abilities grouped under the executive umbrella, matter just as much as memory. A patient may remember that they have tablets, yet still fail to slot the dose into a busy morning routine. Set-shifting difficulties, common in temporal lobe epilepsy, can make rigid timetables feel punishingly hard to maintain.

When executive dysfunction affects daily planning, clinicians sometimes find that simplifying regimens is more effective than reminding patients to try harder. Long-acting formulations, blister packs organised by a partner, and pharmacy-app reminders can offload trial and effort from already-taxed cognitive systems. The principle is shared across disciplines, and similar reasoning shapes choices in hiatal hernia repair, where comorbid load and routine disruption influence recovery.

Mood, anxiety and the motivation to take

Cognitive factors do not operate in isolation. Depression and anxiety, which are common in chronic epilepsy, blunt motivation and amplify avoidance. A patient who believes their medication is not really helping, or who fears side effects, will quietly stop refilling scripts even when memory and executive function are intact.

Screening with brief tools such as the PHQ-9 and GAD-7, alongside neuropsychological testing, allows clinicians to separate the cognitive barrier from the motivational one. Each requires a different intervention: memory aids and simplification for one, supportive counselling and shared goals for the other.

Cultural context and patient beliefs in Australia

Australia's multicultural population shapes how people engage with antiseizure therapy. In communities across Melbourne and western Sydney, traditional views of sickness, the role of family in decision-making, and prior experiences with Western medicine can all influence whether a prescription is filled in the first place. Interpreters and bilingual educators are now standard in many metropolitan services.

Access also varies. The Pharmaceutical Benefits Scheme subsidises most antiseizure medications, but rural patients in regions such as the Pilbara or western Queensland still face long drives to reach a neurologist or a dispensing pharmacy. Telehealth neuropsychology clinics, expanded after the COVID-19 pandemic, have helped close some of that distance.

Embedding cognitive screening in Australian clinics

Routine cognitive screening paired with prescription review remains uncommon outside research settings. Some services are running rolling intake brief computers on tablets in the waiting room, scoring automatically and flagging patients who score below age- and education-adjusted norms. The approach borrows from the future of neuropsychological testing in digital formats, where assessment moves off paper and into everyday clinical flow.

When integrated thoughtfully, such tools surface adherence risk without adding hours to the consultation. They also create a record that can be reviewed at the next appointment, turning a single snapshot into a trajectory.

Research methods and directions ahead

Australian researchers are contributing to international efforts to model adherence as a multidimensional outcome. Multicentre studies drawing on data from Brisbane, Canberra, and Hobart have begun pooling neuropsychological profiles with pharmacy refill records, serum drug levels, and patient-reported adherence measures. The aim is to build predictive models that flag risk early.

For clinicians and students interested in this field, conferences remain a key forum. Anyone preparing work for the next INS meeting can find guidance on how to choose a poster for your research at INS 2018, and the lessons there still apply to current formats.

Practical recommendations for clinical teams

• Pair every prescription review with a brief cognitive screen covering memory and executive function.
• Simplify regimens where possible, choosing long-acting formulations when memory or executive load is flagged.
• Screen for mood and anxiety at every visit, and treat them as adherence interventions in their own right.
• Offer blister packs, pharmacy-app reminders, or partner-supported systems to offload cognitive demands.
• Use culturally appropriate education and interpreters where language or background may shape beliefs about medication.
• Consider telehealth neuropsychology for rural and remote Australians, including those in the Pilbara and western Queensland.
• Track adherence over time using pharmacy refill data alongside self-report, rather than relying on a single measure.